当前位置: 首页 > 期刊 > 《中国现代医生》 > 20206
编号:13503813
舒芬太尼复合罗哌卡因硬膜外麻醉的临床应用效果观察(1)
http://www.100md.com 2020年2月25日 《中国现代医生》 20206
     [摘要] 目的 探討舒芬太尼复合罗哌卡因在硬膜外麻醉中的临床应用效果,为患者的诊疗提供指导。 方法 选取2018年5月~2019年10月于首都医科大学附属北京中医医院接受手术需行硬膜外麻醉的80例患者为研究对象。按照简单随机分组法,将所有患者分为对照组40例和研究组40例。对照组患者予以罗哌卡因麻醉,研究组患者予以舒芬太尼复合罗哌卡因麻醉。对比两组患者的麻醉起效时间、术后血压及心率水平、不同时间点视觉模拟疼痛评分(VAS)评分及麻醉不良反应情况。 结果 研究组患者麻醉起效时间(7.43±0.51)min明显短于对照组(15.46±0.67)min,差异有统计学意义(P<0.05);研究组患者的舒张压、收缩压及心率[(61.15±0.79)mmHg、(100.76±0.65)mmHg、(84.25±5.76)次/min]均明显低于对照组[(76.98±0.47)mmHg、(117.89±0.32)mmHg、(102.31±6.42)次/min],差异有统计学意义(P<0.05);研究组患者麻醉后5 min、10 min、15 min、20 min的VAS评分[(5.44±0.34)分、(4.35±0.34)分、(3.18±0.38)分、(1.42±0.36)分]均明显低于对照组[(8.98±0.73)分、(8.42±0.46)分、(7.36±0.23)分、(5.61±0.42)分],差异有统计学意义(P<0.05);研究组患者麻醉不良反应发生率(5.00%)明显低于对照组(22.50%),差异有统计学意义(P<0.05)。 结论 舒芬太尼复合罗哌卡因在硬膜外麻醉中的临床效果满意,缩短麻醉起效时间,稳定患者血压及心率水平,减轻患者疼痛水平及麻醉不良反应,值得临床广泛应用。

    [关键词] 硬膜外麻醉;舒芬太尼;罗哌卡因;不良反应

    [中图分类号] R614 [文献标识码] B [文章编号] 1673-9701(2020)06-0142-04

    [Abstract] Objective To explore the clinical effect of sufentanil combined with ropivacaine in epidural anesthesia, and to provide guidance for the diagnosis and treatment of patients. Methods 80 patients who underwent surgery and needed epidural anesthesia at Beijing Traditional Chinese Medicine Hospital affiliated to Capital Medical University from May 2018 to October 2019 were selected as the study subjects. All patients were divided into the control group 40 cases and the study group 40 cases according to the simple random grouping method. Patients in the control group were anesthetized with ropivacaine, and patients in the study group were anesthetized with sufentanil combined with ropivacaine. The time of onset of anesthesia, postoperative blood pressure and heart rate, visual analogue pain score (VAS) at different time points and adverse reactions to anesthesia were compared between the two groups of patients. Results The anesthetic onset time (7.43±0.51) min in the study group was significantly shorter than that in the control group (15.46±0.67) min, and the difference was statistically significant(P<0.05). The diastolic blood pressure (61.15±0.79) mmHg, systolic blood pressure(100.76±0.65)mmHg, and heart rate(84.25±5.76)beats per minute in the study group were significantly lower than those of the control group[(76.98±0.47) mmHg, (117.89±0.32) mmHg, (102.31±6.42) beats per minute], and the difference was statistically significant(P<0.05). The VAS scores of patients in the study group at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after anesthesia were [(5.44±0.34) points, (4.35±0.34) points, (3.18±0.38) points, (1.42±0.36) points] , significantly lower than [(8.98±0.73) points, (8.42±0.46) points, (7.36±0.23) points and (5.61±0.42) points] in the control group, and the differences were statistically significant(P<0.05). The incidence of adverse reactions to anesthesia(5.00%) in the study group was significantly lower than that in the control group(22.50%), and the difference was statistically significant(P<0.05). Conclusion The sufentanil combined with ropivacaine in epidural anesthesia has satisfactory clinical effect. It shortens the onset time of anesthesia, stabilizes the blood pressure and heart rate of patients, reduces the pain level of patients and adverse effects of anesthesia. It is worthy of widespread clinical application., http://www.100md.com(陆斌 王麒)
1 2 3下一页